Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease

Molecular Neurobiology

Volumn 52, Issue 3, 2015, Pages 1850-1861

  Ooi, Jolene ^a   Hayden, Michael R ^a,b,c   Pouladi, Mahmoud A ^a,c  

^a AGENCY FOR SCIENCE   (Singapore)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

Human induced pluripotent stem cells; Huntington s disease; Monoamine oxidase; Monoamine oxidase inhibitors; Oxidative stress; Striatal neural cells

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLORGYLINE; HUNTINGTIN; PHENELZINE; SELEGILINE; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; HTT PROTEIN, HUMAN; NERVE PROTEIN; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, MOUSE;

ADULT; AGED; ANIMAL CELL; ARTICLE; CAG REPEAT; CELL STRESS; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MALE; MIDDLE AGED; MOUSE; MUTANT; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PLURIPOTENT STEM CELL; PRESCHOOL CHILD; PROTEIN EXPRESSION; SKIN FIBROBLAST; YOUNG ADULT; ANIMAL; CELL CULTURE; CELL DEATH; DISEASE MODEL; METABOLISM; NERVE CELL; PHYSIOLOGY;

ANIMALS; CELL DEATH; CELLS, CULTURED; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; MICE; MONOAMINE OXIDASE; NERVE TISSUE PROTEINS; NEURONS; OXIDATIVE STRESS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84942817782     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8974-4     Document Type: Article

References (42)

1. Augood SJ, Faull RL, Emson PC (1997) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington’s disease. Ann Neurol 42:215–221. doi:10.1002/ana.410420213
2. Ross CA, Tabrizi SJ (2011) Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83–98. doi:10.1016/S1474-4422(10)70245-3
3. Kish SJ, Shannak K, Hornykiewicz O (1987) Elevated serotonin and reduced dopamine in subregionally divided Huntington’s disease striatum. Ann Neurol 22:386–389. doi:10.1002/ana.410220318
4. Cha JH, Frey AS, Alsdorf SA et al (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington’s disease. Philos Trans R Soc Lond B Biol Sci 354:981–989
5. Shih JC, Chen K, Ridd MJ (1999) Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 22:197–217. doi:10.1146/annurev.neuro.22.1.197
6. Chen JY, Wang EA, Cepeda C, Levine MS (2013) Dopamine imbalance in Huntington’s disease: a mechanism for the lack of behavioral flexibility. Front Neurosci 7:114. doi:10.3389/fnins.2013.00114
7. Renoir T, Argyropoulos A, Chevarin C et al (2014) Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington’s disease. Pharmacol Biochem Behav. doi:10.1016/j.pbb.2014.10.004
8. Reynolds GP, Dalton CF, Tillery CL et al (1999) Brain neurotransmitter deficits in mice transgenic for the Huntington’s disease mutation. J Neurochem 72:1773–1776
9. Bibb JA, Yan Z, Svenningsson P et al (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington’s disease mice. Proc Natl Acad Sci U S A 97:6809–6814. doi:10.1073/pnas.120166397
10. Callahan JW, Abercrombie ED (2011) In vivo dopamine efflux is decreased in striatum of both fragment (R6/2) and full-length (YAC128) transgenic mouse models of Huntington’s disease. Front Syst Neurosci 5:61. doi:10.3389/fnsys.2011.00061
11. Madison JL, Wegrzynowicz M, Aschner M, Bowman AB (2012) Disease-toxicant interactions in manganese exposed Huntington disease mice: early changes in striatal neuron morphology and dopamine metabolism. PLoS One 7:e31024. doi:10.1371/journal.pone.0031024
12. O’Carroll AM, Fowler CJ, Phillips JP et al (1983) The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 322:198–202
13. Antonini A, Leenders KL, Spiegel R et al (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease. Brain 119(6):2085–2095
14. Andrews TC, Weeks RA, Turjanski N et al (1999) Huntington’s disease progression. PET and clinical observations. Brain 122(12):2353–2363
15. van Oostrom JCH, Dekker M, Willemsen ATM et al (2009) Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington’s disease. Eur J Neurol 16:226–231. doi:10.1111/j.1468-1331.2008.02390.x
16. Bortolato M, Shih JC (2011) Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. Int Rev Neurobiol 100:13–42. doi:10.1016/B978-0-12-386467-3.00002-9
17. Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295–309. doi:10.1038/nrn1883
18. Trettel F, Rigamonti D, Hilditch-Maguire P et al (2000) Dominant phenotypes produced by the HD mutation in STHdh (Q111) striatal cells. Hum Mol Genet 9:2799–2809
19. Chen K, Ou X-M, Wu JB, Shih JC (2011) Transcription factor E2F-associated phosphoprotein (EAPP), RAM2/CDCA7L/JPO2 (R1), and simian virus 40 promoter factor 1 (Sp1) cooperatively regulate glucocorticoid activation of monoamine oxidase B. Mol Pharmacol 79:308–317. doi:10.1124/mol.110.067439
20. Wu JB, Chen K, Ou X-M, Shih JC (2009) Retinoic acid activates monoamine oxidase B promoter in human neuronal cells. J Biol Chem 284:16723–16735. doi:10.1074/jbc.M901779200
21. Wong WK, Chen K, Shih JC (2001) Regulation of human monoamine oxidase B gene by Sp1 and Sp3. Mol Pharmacol 59:852–859
22. Ou X-M, Chen K, Shih JC (2006) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci U S A 103:10923–10928. doi:10.1073/pnas.0601515103
23. HD iPSC Consortium (2012) Induced pluripotent stem cells from patients with Huntington’s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11:264–278. doi:10.1016/j.stem.2012.04.027
24. Li W, Sun W, Zhang Y et al (2011) Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. PNAS 108:8299–8304. doi:10.1073/pnas.1014041108
25. Magnani E, Bettini E (2000) Resazurin detection of energy metabolism changes in serum-starved PC12 cells and of neuroprotective agent effect. Brain Res Brain Res Protoc 5:266–272
26. Gerber HP, Dixit V, Ferrara N (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273:13313–13316
27. Sugiyama H, Savill JS, Kitamura M et al (1999) Selective sensitization to tumor necrosis factor-alpha-induced apoptosis by blockade of NF-kappaB in primary glomerular mesangial cells. J Biol Chem 274:19532–19537
28. Veral A, Alper G, Menteş G, Ersöz B (1997) Age and sex related alterations in serum and platelet monoamine oxidase. Eur J Clin Chem Clin Biochem 35:265–268
29. Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2004) Platelet monoamine oxidase activity in subjects tested for Huntington’s disease gene mutation. J Neural Trans (Vienna, Austria: 1996) 111:475–483. doi:10.1007/s00702-003-0103-x
30. Ribeiro M, Silva AC, Rodrigues J et al (2013) Oxidizing effects of exogenous stressors in Huntington’s disease knock-in striatal cells—protective effect of cystamine and creatine. Toxicol Sci 136:487–499. doi:10.1093/toxsci/kft199
31. Gines S, Seong I-S, Fossale E et al (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington’s disease knock-in mice. Hum Mol Genet 12:497–508
32. Seong I-S, Ivanova E, Lee J-M et al (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14:2871–2880. doi:10.1093/hmg/ddi319
33. Mann J, Chiu E (1978) Platelet monoamine oxidase activity in Huntington’s chorea. J Neurol Neurosurg Psychiatr 41:809–812
34. Belendiuk K, Belendiuk GW, Freedman DX (1980) Blood monoamine metabolism in Huntington’s disease. Arch Gen Psychiatry 37:325–332
35. Norman TR, Chiu E, French MA (1987) Platelet monoamine oxidase activity in patients with Huntington’s disease. Clin Exp Pharm Phys 14:547–550
36. Mann JJ, Stanley M, Gershon S, Rossor M (1980) Mental symptoms in Huntington’s disease and a possible primary aminergic neuron lesion. Science 210:1369–1371
37. Mann JJ, Kaplan RD, Bird ED (1986) Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington’s disease compared to schizophrenics and controls. J Neural Trans (Vienna, Austria: 1996) 65:277–283
38. Richards G, Messer J, Waldvogel HJ et al (2011) Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington’s disease revealed by quantitative enzyme radioautography. Brain Res 1370:204–214. doi:10.1016/j.brainres.2010.11.020
39. Mason RP, Casu M, Butler N et al (2013) Glutathione peroxidase activity is neuroprotective in models of Huntington’s disease. Nat Genet 45:1249–1254. doi:10.1038/ng.2732
40. Fitzgerald JC, Ugun-Klusek A, Allen G et al (2014) Monoamine oxidase-A knockdown in human neuroblastoma cells reveals protection against mitochondrial toxins. FASEB J 28:218–229. doi:10.1096/fj.13-235481
41. Li S-H, Cheng AL, Zhou H et al (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22:1277–1287
42. Dunah AW, Jeong H, Griffin A et al (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington’s disease. Science 296:2238–2243. doi:10.1126/science.1072613